Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122626) titled 'Clinical Study on the Efficacy and Safety of Jaktinib Combined with Donafenib and Immunotherapy in Second-Line Treatment of Unresectable Hepatocellular Carcinoma' on April 15.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Yunnan Cancer Hospital

Condition: Hepatocellular carcinoma

Recruitment Status: Not Recruiting

Phase: 1

Date of First Enrollment: 2026-04-15

Target Sample Size: experimental group:35;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=308232

Published by HT Digital Content Services with permission from Hea...